Amicus Therapeutics Enters a ~$590M Exclusive License Agreement with Dimerix for DMX-200
Shots:
- Dimerix has granted Amicus exclusive US rights to develop & market DMX-200 for all indications, incl. focal segmental glomerulosclerosis (FSGS), with Amicus handling regulatory filings, dossier maintenance, & marketing in the US
- Dimerix will get $30M cash upfront, ~$75M on FDA approval, $35M on 1st sale, ~$40M for future indications & ~$410M in sales milestones, plus tiered royalties on net sales (low teens to low twenties %); they will also form a joint steering committee to align US development & marketing of DMX-200 for FSGS
- Dimerix will fund & execute the P-III (ACTION3) trial, with full enrollment expected by end-2025. A blinded interim analysis is planned after finalization of revised EPs in the protocol & FDA agreement
Ref: Globenewswire | Image: Amicus Therapeutics & Dimerix
Related News:- Henlius and Sandoz Enter a Global Collaboration Agreement to Commercialize HLX13 (Biosimilar, Yervoy)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
